Tyrosine kinase inhibitor

For research use only. Not for therapeutic Use.

  • CAT Number: I000153
  • CAS Number: 1021950-26-4
  • Molecular Formula: C31H31FN6O5
  • Molecular Weight: 586.61
  • Purity: ≥95%
Inquiry Now

Tyrosine kinase inhibitor is a potent tyrosine kinase inhibitor.
Tyrosine kinases are important mediators of the signaling cascade, determining key roles in diverse biological processes like growth, differentiation, metabolism and apoptosis in response to external and internal stimuli[1].


Catalog Number I000153
CAS Number 1021950-26-4
Synonyms

1-N’-(4-fluorophenyl)-1-N-[4-[[2-(2-morpholin-4-ylethylcarbamoyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]cyclopropane-1,1-dicarboxamide

Molecular Formula C31H31FN6O5
Purity ≥95%
InChI InChI=1S/C31H31FN6O5/c32-20-1-3-21(4-2-20)35-29(40)31(10-11-31)30(41)36-22-5-7-23(8-6-22)43-26-9-12-33-27-24(26)19-25(37-27)28(39)34-13-14-38-15-17-42-18-16-38/h1-9,12,19H,10-11,13-18H2,(H,33,37)(H,34,39)(H,35,40)(H,36,41)
InChIKey PKOVTRMHYNEBDU-UHFFFAOYSA-N
SMILES C1CC1(C(=O)NC2=CC=C(C=C2)OC3=C4C=C(NC4=NC=C3)C(=O)NCCN5CCOCC5)C(=O)NC6=CC=C(C=C6)F
Reference

[1]. Paul MK, et al. Tyrosine kinase – Role and significance in Cancer. Int J Med Sci. 2004;1(2):101-115.
 [Content Brief]

[2]. Inoue T, et al. Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma. World J Surg Oncol. 2012 Aug 20;10(1):167.
 [Content Brief]

[3]. Bowen JM, et al. Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea. Cancer Biol Ther. 2012 Nov 1;13(13).
 [Content Brief]

[4]. Sun FK, et al. Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma. Chin Med J (Engl). 2012 Jun;125(12):2231-4.
 [Content Brief]

[5]. Thamm DH. Tyrosine kinase inhibitor special issue. Vet Comp Oncol. 2012 Sep;10(3):161-2. doi: 10.1111/j.1476-5829.2012.00339.x.
 [Content Brief]

[6]. Eriksson A, et al. The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia. Blood Cancer J. 2012 Aug 3;2:e81. doi: 10.1038/bcj.2012.28.
 [Content Brief]

Request a Quote